Future Oncology

Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer

To assess real-world progression-free survival (rwPFS) and time to next treatment (rwTTNT) among patients with epithelial ovarian cancer (EOC) who received first-line maintenance (1LM) niraparib monotherapy. In this US-nationwide, electronic health record-derived, deidentified database study, eligible patients with EOC initiated 1LM niraparib monotherapy (1 January 2017-1 December 2022) following first-line platinum-based chemotherapy. Median rwPFS and rwTTNT were estimated with Kaplan-Meier methodology overall and in a homologous recombination-deficient (HRd) subgroup (further stratified as Observed median rwPFS was 11.4 (95% CI, 10.1-12.7) months overall ( The real-world observed median rwPFS and rwTTNT were longer for patients with EOC who received 1LM niraparib monotherapy in the HRd subgroup (specifically for the

Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary

Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer

At first recurrence, platinum-sensitive ovarian cancer (PSOC) is frequently treated with platinum-based chemotherapy doublets plus bevacizumab, then single-agent bevacizumab. Most patients' disease progresses within a year after chemotherapy, emphasizing the need for novel strategies. Mirvetuximab soravtansine-gynx (MIRV), an antibody-drug conjugate, comprises a folate receptor alpha (FRα)-binding antibody and tubulin-targeting payload (maytansinoid DM4). In FRα-high PSOC, MIRV plus bevacizumab previously showed promising efficacy (objective response rate, 69% [95% CI: 41-89]; median progression-free survival, 13.3 months [95% CI: 8.3-18.3]; median duration of response, 12.9 months [95% CI: 6.5-15.7]) and safety. The Phase III randomized GLORIOSA trial will evaluate MIRV plus bevacizumab vs. bevacizumab alone as maintenance therapy in patients with FRα-high PSOC who did not have disease progression following second-line platinum-based doublet chemotherapy plus bevacizumab.

Unmet needs and emerging therapeutics in low-grade serous ovarian carcinoma: from chemoresistance to precision medicine

Low-grade serous ovarian carcinoma (LGSOC) is a rare and clinically distinct subtype of ovarian cancer, which presents unique challenges in diagnosis and treatment. LGSOC is characterized by low proliferation rates, high expression of hormone receptors, and frequent alterations in the mitogen-activated protein kinase (MAPK) pathway. Initial standard treatment includes cytoreductive surgery followed by platinum-based chemotherapy and endocrine therapy. However, high recurrence rates (~80%) and poor responses to chemotherapy underscore the urgent need for new treatment strategies. Endocrine therapy is being investigated in the upfront setting, and recent advances in targeted therapies, including MAPK pathway inhibitors and investigational agents such as cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, are shaping the evolving LGSOC treatment landscape. Notably, the recent US Food and Drug Administration approval of the avutometinib/defactinib combination for

Identification of an Immune-Based mRNA–lncRNA Signature for Overall Survival in Cervical Squamous Cell Carcinoma

Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis

Evidence from Europe on implementation, participation and performance of self-collection for cervical cancer screening

Cervical cancer screening programs reduce the number of cervical cancer cases and deaths, but the success of any screening program is dependent on high participant uptake and coverage and many European countries are observing declining cervical cancer screening coverage to below national targets. Self-collection of vaginal samples for human papillomavirus testing, also termed self-sampling, is one strategy which is being introduced to try to increase screening coverage by removing barriers to participation and it has attracted growing interest and support globally. Informed by peer-reviewed and gray literature, this narrative review starts with a case study from the Netherlands and outlines the self-collection landscape in Europe within the themes of program implementation and relative test performance. It highlights some of the current evidence gaps needed to inform policy decisions on the use of self-collection within screening programs.

Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer

Mirvetuximab soravtansine (MIRV) is FDA-approved for platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression. In the MIRASOL trial, MIRV improved median progression-free survival (5.6 vs. 3.9 months) and overall survival (16.5 vs. 12.8 months; HR 0.67) over chemotherapy. MIRV has a favorable safety profile but is associated with unique ADC-related toxicities, including blurred vision, keratopathy, and nausea. Ocular side effects are managed with regular eye exams and prophylactic drops, with no permanent damage reported. MIRV has also shown promising results in combination with bevacizumab and with carboplatin in platinum-sensitive disease. Ongoing research aims to optimize ADC components and explore synergistic combinations to expand MIRV's role in FRα-expressing ovarian cancer.

The benefits and pitfalls of adding bevacizumab to neoadjuvant chemotherapy for advanced ovarian cancer: a meta-analysis

To appraise the efficacy and toxicity of adding bevacizumab to neoadjuvant chemotherapy (NACT) for advanced-stage ovarian cancer (AOC). All studies regarding neoadjuvant bevacizumab for AOC published in PubMed, EMBASE, Scopus and Web of Science from 1 November 2010 to 31 December 2024 were retrieved and reviewed. Three randomized clinical trials, five retrospective cohort studies, and six case series were eligible, including 687 patients receiving bevacizumab-NACT and 1482 patients receiving standard-NACT. There were no significant differences between the bevacizumab-NACT group and the standard-NACT group in the rates of interval debulking surgery implementation, achieving complete cytoreduction, wound complication, thrombogenesis, and infections (grade ≥3). The rate of achieving optimal cytoreduction in bevacizumab-NACT group was significantly higher than that in standard-NACT group (RR: 1.17, 95% CI: 1.02 to 1.34, P = 0.02; I Adding bevacizumab to NACT for AOC can enhance the feasibility of optimal cytoreduction, rather than complete cytoreduction. However, bevacizumab-NACT increased the risk of gastrointestinal perforation. www.crd.york.ac.uk/prospero identifier is CRD42024566484.

Real-world data from patients with gastric-type mucinous carcinoma of the cervix: a multicenter, retrospective study

We herein retrospectively analyzed the clinicopathologic features from a large cohort of GAS patients to provide real-world evidence for optimizing the diagnosis and treatment. One hundred and fifty-seven GAS patients from three hospitals were recruited for analysis. We extracted clinical and pathologic information from patient medical records and performed regular follow-up. Logistic regression and Kaplan - Meier analyses were conducted to identify the prognostic factors. 31.2% exhibited stage I tumor, and 11.5%, 33.1%, and 24.2% manifested tumors at stages II, III, and IV, respectively. For the entire group, the median progression-free survival (PFS) and overall survival (OS) were 22 and 33 months, respectively. Multivariate analysis showed tumor stage and ovarian metastasis were predictors for PFS; and that ovarian metastasis and small tumor diameter were independent prognostic factors for OS. We determined an abnormal elevation of tumor abnormal protein (TAP) in 76% GAS patients, which could serve as a sensitive marker for tumor recurrence/metastasis. We demonstrated that ovarian metastasis and FIGO stage (including tumor diameter) were independent prognostic predictors for GAS patients. Moreover, we were the first to report that TAP constituted a potent marker for GAS surveillance, thus warranting further investigation.

Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success

Testing for tumor BRCA mutations and homologous recombination deficiency (HRD) is recommended for all patients with advanced high-grade epithelial ovarian cancer. Delays in the HRD testing process can significantly affect the treatment offered to patients. HRD testing pathways and sampling processes were analyzed for tests sent from a tertiary gynae-oncology referral center between December 2020 and January 2023. A total of 148 hRD tests were performed in 125 patients. The overall success rate of HRD testing was 69.6%. The success rates of obtaining results were: from diagnostic image-guided biopsy 66.7% ( By optimizing the factors affecting HRD test success, we can obtain faster results and offer patients appropriate treatment at earlier time points to improve patient outcomes.

Diagnosis, treatment and burden in advanced ovarian cancer: a UK real-world survey of healthcare professionals and patients

OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer

A consensus regarding subsequent therapeutic strategies for patients with platinum- and poly (ADP-ribose) polymerase inhibitor (PARPi)-resistant ovarian cancer is lacking. These patients typically receive non-platinum-based chemotherapy; however, survival outcomes remain poor. Compared with chemotherapy alone, combination therapy with novel target agents can provide additional benefits to these patients. Oregovomab, an investigational murine monoclonal antibody against CA-125, has shown promising efficacy in a phase II study in patients with recurrent ovarian cancer. Herein, we described the rationale and design of OPERA/KGOG 3065/APGOT-OV6, a multicenter, investigator-initiated, two-cohort, single-arm phase II trial, aimed at examining the efficacy of oregovomab plus non-platinum-based chemotherapy in patients with PARPi/platinum-resistant ovarian cancer. The primary end point was the objective response rate, according to RECIST 1.1.

OCEANIA: real-world study of ovarian cancer treatment patterns across multiple lines of therapy in Argentina and Brazil

Hyperthermic Intraperitoneal Chemotherapy in Locally Advanced and Recurrent Ovarian Carcinoma: Surgical and Oncological Outcomes in the Indian Public Healthcare System

This study analyzed the surgical outcomes after initial implementation of a cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) program in government settings in India.

Poly(ADP-Ribose) Polymerase Inhibitors in Combination with Anti-Angiogenic Agents for the Treatment of Advanced Ovarian Cancer

Homologous recombination deficiency and VEGF expression are key pathways in high-grade ovarian cancer. Recently, three randomized practice changing trials were published: the PAOLA-1, PRIMA and VELIA trials. The use of PARP inhibitors (PARPi) following chemotherapy has become standard of care in first line. Combination of PARPi with anti-angiogenic agents has demonstrated synergistic activity in preclinical study. This review summarizes the body of evidence supporting the efficacy and safety of the combination of PARPi and anti-angiogenic drugs in first-line homologous recombination deficiency high-grade ovarian cancer leading to US FDA and EMA approvals. This double maintenance is supported by: a large benefit with bevacizumab + olaparib compared with olaparib alone, a rationale for additive effect, and a good safety and cost-effective profile.

EPIK-O/ENGOT-OV61: Alpelisib Plus Olaparib vs Cytotoxic Chemotherapy in High-Grade Serous Ovarian Cancer (Phase III Study)

Patients with platinum-resistant or -refractory high-grade serous ovarian cancer (HGSOC) have a poor prognosis, and their management represents a substantial unmet medical need. Preclinical data and results from a phase Ib trial demonstrated the efficacy and tolerability of the combination of the α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib plus the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib in platinum-resistant, non-

Molecular Methods for Increasing the Effectiveness of Ovarian Cancer Treatment: A Systematic Review

Building a Predictive Model to Assist in the Diagnosis of Cervical Cancer

Utility of a Metabolic-Associated Nomogram to Predict the Recurrence-Free Survival of Stage I Cervical Cancer

Analysis of Clinical Characteristics and Prognosis with Cervical Adenosquamous Carcinoma: a Large Population-Based Study

Evaluation of a multimodal ctDNA-based assay for detection of aggressive cancers lacking standard screening tests

HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors

Fibrinolysis markers as predictive indicators of neoadjuvant chemotherapy efficacy in ovarian cancer patients

Ovarian cancer (OC) is a prevalent gynecological malignancy with high mortality due to its asymptomatic progression and advanced stage at diagnosis. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is beneficial for patients unsuitable for primary debulking surgery (PDS). Effective markers for assessing NACT outcomes could significantly aid clinical decision-making and personalized treatment strategies. In this retrospective study, we examined fibrinolytic markers, including D-dimer, fibrinogen (FIB), and fibrinogen degradation products (FDP), among 167 OC patients and 110 healthy controls. Plasma levels of these markers were measured before and after four NACT cycles in OC patients, and receiver operating characteristic (ROC) analysis was conducted to evaluate their diagnostic and predictive value. OC patients exhibited significantly elevated baseline levels of D-dimer, FIB, and FDP compared to healthy controls. Post-NACT measurements showed that responders had a substantial decrease in these markers, while non-responders showed minimal changes. ROC analysis confirmed the diagnostic accuracy of D-dimer, FIB, and FDP, with high sensitivity and specificity for predicting NACT effectiveness. D-dimer, FIB, and FDP are elevated in OC patients and demonstrate a potential role as noninvasive markers for assessing NACT efficacy, offering valuable insights for treatment planning.

Post-surgery recurrence predictors for stage I-II endometrial carcinoma: a retrospective observational study

A retrospective observational study was conducted to investigate the predictors for recurrence of stage I-II endometrial cancer after surgical treatment. 130 stage I-II endometrioid carcinoma patients receiving laparoscopic surgery in Jincheng People's Hospital from January 2019 to January 2022 were retrospectively selected and diagnosed via HE assay. Their clinic and histology characteristics were collected. Kaplan-Meier survival analysis was to analyze the effect of chemotherapy and radiotherapy on the survival rate of the recurrent patients. Multivariate analysis was to explore the factors affecting postoperative recurrence. Diagnosis was confirmed by diagnostic curettage in 129 cases. In 130 patients, the invading of superficial myometrium and deep myometrium was more obvious. After chemotherapy and radiotherapy treatment, the 5-year survival rate was 78.46%, and it was different among two therapies; ( The Stage I-II endometrial cancer recurrence after laparoscopic surgery can be judged by pathological type, disease stage, histological grade and myometrial invasion, providing theoretical basis for disease treatment to reduce the recurrence and improve the prognosis.

Homologous recombination deficiency in pancreatic neuroendocrine tumors

Efficacy of PD-1/PDL-1 inhibitors for ovarian cancer: a systematic review and network meta-analysis

Randomized controlled trials (RCTs) have assessed the efficacy of anti-programmed cell death 1 (PD- 1)/programmed cell death ligand 1 (PD-L1), alone or combined with other therapies, for ovarian cancer. However, the optimal strategy remains unclear. This study evaluated their effectiveness as monotherapy and in combination. We conducted a systematic review and Frequentist network meta-analysis (NMA) by searching PubMed, ScienceDirect, Web of Science, Scopus, Cochrane Library, and Clinicaltrials.gov databases. This analysis included RCTs comparing PD-L1/PD-1 inhibitors, alone or in combination with other therapies. Six studies involving 3,895 patients and eight treatment combinations were included. PD1/PDL1 inhibitors plus chemotherapy and PD1/PDL1 inhibitors plus ipilimumab showed the greatest progression-free survival (PFS) benefit (hazard ratio (HR) = 0.82, 95% confidence interval [CI]: 0.52-1.07; HR = 0.82, 95% CI:0.51-1.33) and overall survival (OS) (HR = 0.85, 95% CI:0.64-1.14; HR = 0.83, 95% CI:0.45-1.54). These combinations also improved overall response rates (ORR), especially with chemotherapy (OR = 3.06; 95% CI:1.42-6.60). Subgroup analysis suggested that PD-1/PD-L1 inhibitors plus chemotherapy provided the best PFS and OS in PD-L1-positive patients. Combining PD-1/PD-L1 inhibitors with chemotherapy or ipilimumab improved survival in ovarian cancer. However, PD-L1 expression may be a valuable biomarker for predicting the efficacy of PD-1/PD-L1 checkpoint inhibitors. This systematic review was preregistered in PROSPERO (CRD42022342057). Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD42022347967.

Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023)

Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US

To describe first-line maintenance (1LM) treatment patterns since 1 January 2020, for real-world patients with newly diagnosed advanced ovarian cancer (aOC). This retrospective study used a US-nationwide electronic health record-derived deidentified database. Eligible patients were aged ≥ 18 years with stage III/IV epithelial OC and initiated first-line platinum-based chemotherapy±bevacizumab (index; 01Jan2020-28Feb2023). Baseline characteristics and 1LM treatment patterns were summarized overall and by Among 599 eligible patients (median [interquartile range] age, 67 [59-74] years; 59.8% White; 50.3% stage III disease), 15.5% had Fewer than half of included patients with aOC received 1LM treatment in the real-world setting. More work is needed to understand reasons underlying real-world 1LM treatment choice for patients with aOC.

Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey

To explore physician-reported knowledge, use, and perceptions of genetic testing for advanced ovarian cancer management. Gynecology/oncology specialists ( Physician-reported breast cancer gene mutation (BRCAm) testing rates increased over the 2 years before the survey; most patients underwent testing in the preceding 6 months. Homologous recombination deficiency (HRD) genomic instability testing rates and physicians' confidence interpreting results remained relatively low. Genetic testing was driven by the associated treatment implications of the findings. Poor performance status, inadequate tissue, and patients' willingness to undergo testing were reported barriers to testing. Findings indicate that there is a need to improve both access to and information about HRD testing.

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy

Real-world first-line treatment patterns and outcomes in recurrent/advanced endometrial cancer patients in Europe

Prognostic value of the glucose-to-lymphocyte ratio in surgically treated endometrial cancer: a retrospective cohort study

The glucose-to-lymphocyte ratio (GLR) has recently gained attention as a composite biomarker reflecting systemic inflammation and metabolic dysregulation. While its prognostic value has been reported in various malignancies, its clinical utility in endometrial cancer remains unknown. This study aimed to evaluate the prognostic relevance of GLR in surgically treated patients with endometrial cancer. We retrospectively analyzed 165 patients who underwent total abdominal hysterectomy for endometrial cancer between January 2021 and January 2025. GLR was calculated by dividing fasting glucose levels by absolute lymphocyte count. Patients were classified into GLR-high and GLR-low groups using the median value (3.70). Disease-free survival (DFS) and overall survival (OS) were compared using Kaplan - Meier curves and Cox regression analysis. The median follow-up was 17.4 months. High GLR was independently associated with shorter DFS (HR: 2.05; 95% CI: 1.08-3.89; GLR is an independent prognostic factor for DFS in endometrial cancer and may serve as a readily available, cost-effective biomarker. Further prospective studies are needed for validation.

Clinical risk factors and predictive value of inflammatory biomarkers for 2-year recurrence after standard surgery for endometrial cancer: a retrospective study among the Chinese population

This study aimed to identify risk factors for recurrence after surgery for endometrial carcinoma in Chinese patients and to develop a postoperative surveillance model integrating preoperative biomarkers with postoperative pathological features. We retrospectively reviewed the clinical records of pathologically diagnosed endometrial cancer patients who underwent surgical treatment between January 2019 and December 2022. Patients were stratified into recurrence (n = 80) and non-recurrence (n = 282) cohorts based on 2-year follow-up results (median follow-up: 46 months). Data collected included demographics, postoperative pathological features, treatment details, and preoperative laboratory indices. Multivariable logistic regression identified advanced postoperative International FIGO stage, larger postoperative tumor size, higher preoperative pan-immune-inflammation value (PIV), and elevated preoperative C-reactive protein (CRP) as independent risk factors for recurrence, while higher preoperative albumin (Alb) was a protective factor (all Advanced FIGO stage, larger tumor size, elevated PIV and CRP, and reduced albumin are key predictors of recurrence. Combining these factors provides a strong model for individualized postoperative surveillance.

Detecting metabolic signatures in endometrial cancer: potential applications of Raman spectroscopy

Endometrial cancer (EC) is intricately linked to obesity, with metabolic reprogramming increasingly established to drive oncogenic transformation and influence treatment outcomes. Implementation of early detection strategy significantly reduces morbidity and mortality; however, screening strategies lack the required sensitivity, specificity, and accuracy to be successfully implemented in clinical practice. Current diagnostic approaches are also invasive, costly, and time-consuming, highlighting a gap in developing diagnostic and screening alternatives for EC among high-risk individuals, especially with sensitivity to capture cancer-specific changes. Raman Spectroscopy is an emerging tool in medical diagnostics. By exploiting the atomic vibrational absorption induced by the interaction of light with a biological sample, a unique spectral response namely a "metabolite fingerprint" can be generated. This nondestructive technique combined with multivariate statistical analysis can characterize metabolic discrimination between cancerous and healthy samples, demonstrating a promising role in cancer screening, diagnosis, and monitoring of treatment outcomes. This review aimed to collate available evidence on Raman's ability to capture metabolic abnormalities, particularly cancer-specific metabolites during malignant transformation and therapeutic resistance. Given that cellular metabolism is altered in EC, this review will provide insight into its potential applications for EC screening, diagnosis, and prospects, especially for monitoring treatment outcomes among high-risk patients.

The broad societal value of pembrolizumab for women’s cancer in Canada

The impact of women's cancers is multifaceted, with broad societal and economic consequences. Health technology assessments often rely solely on costs and outcomes directly relevant to the healthcare system. Our study incorporates the additional and novel value elements across three perspectives for pembrolizumab in four women's cancers in a Canadian setting. We analyzed the net monetary benefit (NMB) of pembrolizumab-based treatments of early-stage triple-negative breast cancer, metastatic triple-negative breast cancer, microsatellite instability-high endometrial cancer, and cervical cancer from three perspectives: traditional payer perspective (TPP), traditional societal perspective (TSP), and broad societal perspective (BSP). Indications and comparators were modeled independently, combined, and weighted by prevalence. Pembrolizumab-based therapy generated an NMB over four times greater with the BSP (Canadian dollars, CAD$925,078), compared with TPP (CAD$226,090) and TSP (CAD$222,556). The largest driver of results was the inclusion of insurance value. Results excluding insurance value still generated an NMB of CAD$484,384, more than twice the TPP. Broadening the perspective to include additional value elements considerably increased the overall value of treatment of women's cancer compared with the TPP, indicating that the perspective used by health technology bodies may not fully capture the societal value of therapeutics.

DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients

Immunotherapy (IO) in endometrial cancer (EC) is the standard of care in the second line setting in combination with an anti-angiogenic agent. Randomized clinical trials have reported results supporting the addition of IO to chemotherapy (paclitaxel plus carboplatin) in the first-line setting in advanced EC patients in the global population, with high efficacy in mismatch repair deficient (MMRd) patients. These trials were not designed to answer this de-escalation question in the MMRd population, who benefit greatly from IO.The international, randomized phase III, DOMENICA trial compares first-line dostarlimab versus chemotherapy alone (with planned cross-over) for advanced MMRd EC. Our primary endpoint will be progression-free survival. The key secondary endpoints will be overall survival, safety and quality of life [NCT05201547].

An MRI-based radiomics nomogram to predict progression-free survival in patients with endometrial cancer

Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression

Vasculogenic mimicry in human cancers associated with chronic high-risk human papillomavirus infection

Vasculogenic mimicry (VM) allows tumor cells to form vessel-like channels, promoting growth, metastasis, and therapy resistance. Persistent infection with high-risk human papillomavirus (HPV), mainly types 16 and 18, is a key factor in various cancers, including anogenital and head and neck cancers. VM has been documented in cervical cancer and oral squamous cell carcinoma (OSCC), but its role in other HPV-associated cancers remains unexplored. This review summarizes literature published between October 2024 and April 2025 in PubMed and Google Scholar, focusing on VM in HPV-related cancers. General mechanisms highlighted include epithelial-mesenchymal transition, hypoxia, and activation of STAT3 and PI3K/AKT pathways. Molecular regulators include TXNDC5, CHI3L1, erythropoietin, and microRNAs miR-124 and miR-29b in cervical cancer; and collagen XVI, LGR5, ALDH1, Beclin 1, VE-cadherin, CD44, HIF-1α, and SOX7 in OSCC. From a translational perspective, elucidating the molecular regulators of VM could reveal therapeutic opportunities through strategies targeting specific signaling pathways in tumor cells.

Knowledge, attitudes, and practices regarding HPV infection, cervical cancer, and HPV vaccination among Emirati women

This study aimed to investigate knowledge, attitudes, and practices (KAPs) regarding human papillomavirus (HPV) infection, cervical cancer (CC), and HPV vaccination among Emirati women with the goal of informing the development of targeted public health interventions. A community-based, cross-sectional study was conducted among Emirati women from January to May 2024 among Emirati women. A systematic sampling approach was used to recruit participants from Zayed University, Ajman University, and Al Tawam Hospital, in which context every third eligible adult female visitor was invited to participate in this research. The main outcome measures were KAPs practices regarding HPV infection, cervical cancer, and HPV vaccination. The study included 216 Emirati women (median age: 21 years, range: 18-60 years). While 64.4% of the participants reported good knowledge about HPV infection and CC, only 58.3% reported good knowledge regarding HPV vaccination. Negative attitudes toward HPV infection and CC were reported by 76.9% of the participants. Preventive practices were reportedly high (72.2%), but only 28.2% of the participants had actually received the HPV vaccination. Despite relatively high levels of CC awareness, misconceptions about HPV transmission and vaccination persist among Emirati women. Enhancing health education, involving healthcare providers, and addressing cultural concerns are essential for efforts to improve HPV prevention strategies and increase vaccine uptake in the United Arab Emirates (UAE).

TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer

Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are offered to prolong intervals between lines of chemotherapy. Current maintenance options involve bevacizumab and poly ADP-ribose polymerase inhibitors, but these lines of therapy can only be used once in the disease course. Patients in first or second platinum sensitive relapse after poly ADP-ribose polymerase inhibitors and bevacizumab represent an area of unmet medical need. This academic sponsored, international Phase II randomized trial is evaluating the combination of a therapeutic cancer vaccine (OSE2101) with anti-PD1 (pembrolizumab) as maintenance therapy, in patients with platinum-sensitive recurrence regardless of number of prior lines and no progression after platinum-based chemotherapy.

Efficacy and safety of VEGFR inhibitors for recurrent ovarian cancer: a systematic review

Trends and frontiers of maintenance therapy for ovarian cancer over the past 20 years: a bibliometric analysis

Efficacy and Safety of Bevacizumab in Patients with Low-Grade Serous Ovarian Cancer

Prevalence and predictors for cisplatin-induced toxicities in Zimbabwean women with cervical cancer

PD-1 inhibitor plus concurrent chemoradiotherapy for high-risk locally advanced cervical cancer

Truscreen Detection of Cervical Tissues for High-Risk Human Papillomavirus-Infected Women During the COVID-19 Pandemic

The Power of Hope: Views of Ovarian Cancer Patients on How Maintenance Therapy Affects Their Lives (VOCAL)

Real-World Utilization of Lenvatinib and Pembrolizumab Combination Therapy for the Treatment of Endometrial Cancer in the USA

Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study

Treatment patterns and outcomes by mismatch repair/microsatellite instability status among patients with primary advanced or recurrent endometrial cancer in the United States

To describe real-world patient characteristics, treatment patterns, and clinical outcomes in primary advanced/recurrent endometrial cancer (pA/R EC) by mismatch repair/microsatellite instability (MMR/MSI) status who initiated first-line therapy. Data from the Flatiron Health electronic health record-derived database were analyzed from patients with a diagnosis of pA/R EC who started treatment between 1 January 2013, and 31 August 2022, from ≈ 280 US clinics. MMR/MSI status and treatment patterns were summarized; time to next treatment (TTNT) and overall survival (OS) were estimated using Kaplan-Meier methods. Of 2022 patients, 11.03%, 27.79%, and 61.18% had MMR-deficient/MSI-high (dMMR/MSI-H), MMR-proficient/microsatellite stable (MMRp/MSS), and unknown MMR/MSI status, respectively. Platinum-based chemotherapy combinations, including carboplatin-paclitaxel, were the most frequent first-line regimens (dMMR/MSI-H, 49.33%; MMRp/MSS, 55.52%; unknown, 65.08%); treatment patterns differed between subgroups. Median TTNT with platinum-based combinations were 6.87, 8.08, and 7.85 months, respectively; OS medians were 41.89, 26.18, and 21.62 months, respectively. Platinum-based chemotherapy combinations, the recommended first-line treatment, were not used in ≈ 40% of patients. TTNT rates were similar to the PFS rates in the carboplatin-paclitaxel arms in the RUBY and GY-018 trials; OS rates were similar to RUBY, highlighting the potential for combination therapies to improve outcomes.